Penningtons Manches Cooper advises medtech business Orthox on $12.5 million Series A financing round
The corporate team at Penningtons Manches Cooper has advised Oxford University spin-out Orthox Limited on the completion of a further $4.3 million (£3.2 million) to close its $12.5 million (£9.2 million) Series A financing round.
The financing will support further clinical trials of its lead product, FibroFix™, at Southmead Hospital Bristol, UK and in Budapest, Hungary.
Orthox is a clinical stage company developing medical devices to repair damaged cartilage and other orthopaedic injuries. Orthox’s FibroFix™ technology, originating from Oxford University, is a revolutionary tissue scaffold based on fibroin, a tissue regenerative protein extracted from silk fibres. FibroFix™ products have the potential to address an annual market in the knee joint alone estimated at over $2 billion.
Penningtons Manches Cooper has advised Orthox since early in its development on a range of corporate and other matters. The team who advised on this latest round of funding was led by corporate partner James Went and included support from corporate tax associate Leonie Langley on EIS matters.
Commenting on the financing, Nick Skaer, co-founder and CEO of Orthox said:
“This $12.5 million Series A financing round from a range of high quality medtech investors reflects the strong progress we are making with our award winning FibroFix product platform. I’d like to thank James Went and the Penningtons Manches Cooper team for their continued support and expertise as we continue our journey.”
James Went, corporate partner at Penningtons Manches Cooper said:
“We are delighted to have advised Orthox on their latest funding round. It’s a great team and company with fantastic potential to help people with orthopaedic injuries. We look forward to continuing to support them as they take their technology forward.” The current financing was led by Parkwalk, the UK’s most active investor in the university spin-out sector, joined by existing shareholders including Oxford Technology & Innovations EIS Fund (OTIF), advised by Oxford Investment Consultants LLP, and Perivoli Innovations. New investors participating include life science fund managers, Additio Investment Group.
More in Finance
Unipart announces financial results for the year ended 31 December 2023
Unipart delivers strong growth and revenues exceed £1bn
Charles Stanley ...
Established in 1792, Charles Stanley is one of the UK’s leading wealth management firms, with a rich heritage of delivering high quality client service. Although we are more than 200 years old, we are focused on investing in our future, embracing technology and innovation, and adapting to changes in society to help our clients prosper. Operating from more than 20 branches across the UK we provide bespoke investment portfolios and tailored financial advice at every stage of your financial journey.
Your FREE guide to the Spring Budget 2023
Chancellor, Jeremy Hunt’s Budget 2023 revolved around the theme of back-to-work through the extension of free childcare, and the lifting of pension caps.
From this author
PENNINGTONS MANCHES COOPER ADVISES THE SHAREHOLDERS OF OXLID ON ITS ACQUISITION...
The corporate team at Penningtons Manches Cooper has advised the shareholders of UK-based OXLiD on its acquisition by AIM listed Anglo-Australian battery innovator, Gelion.
PENNINGTONS MANCHES COOPER APPOINTED AS LEGAL ADVISOR TO ADVANCED RESEARCH +...
Penningtons Manches Cooper’s Birmingham and Oxford offices have been appointed as legal advisors to the Advanced Research + Invention Agency (ARIA), a new R&D agency built to unlock scientific and technological breakthroughs to benefit everyone.
PENNINGTONS MANCHES COOPER ADVISES THE SHAREHOLDERS OF MACHINE VISION TECHNOLOGY SPECIALISTS...
The corporate team at Penningtons Manches Cooper has advised the shareholders of machine vision technology specialists Industrial Vision Systems on its acquisition by Oxford Metrics PLC (LSE: OMG).